Wecome Pharmaceutical Co Ltd (300878) — Capital Reinvestment Ratio

Latest as of June 2025: 0.01x

Wecome Pharmaceutical Co Ltd (300878) has a Capital Reinvestment Ratio of 0.01x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥50.89 Million) in capital expenditures (CN¥389.97K). Check Wecome Pharmaceutical Co Ltd (300878) tangible net worth to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥50.89 Million
CNY

Capital Expenditures

CN¥389.97K
CNY

Data as of

Jun 2025
Most recent filing

Wecome Pharmaceutical Co Ltd Capital Reinvestment Ratio (2013–2023)

This chart tracks Wecome Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Wecome Pharmaceutical Co Ltd (300878) cash flow conversion.

Annual Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd (2013–2023)

Year-by-year Capital Reinvestment Ratio for Wecome Pharmaceutical Co Ltd from 2013 to 2023. See 300878 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2023 2.39x CN¥58.29 Million CN¥139.29 Million ▲ +41.0%
2022 1.70x CN¥146.57 Million CN¥248.44 Million ▼ -52.4%
2020 3.56x CN¥42.81 Million CN¥152.34 Million ▲ +249.0%
2019 1.02x CN¥112.76 Million CN¥114.98 Million ▼ -37.7%
2018 1.64x CN¥105.57 Million CN¥172.73 Million ▲ +12.9%
2017 1.45x CN¥29.00 Million CN¥42.04 Million ▲ +202.7%
2016 0.48x CN¥100.15 Million CN¥47.97 Million ▼ -63.1%
2015 1.30x CN¥29.63 Million CN¥38.48 Million ▲ +46.9%
2014 0.88x CN¥46.01 Million CN¥40.68 Million ▲ +100.2%
2013 0.44x CN¥25.98 Million CN¥11.48 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow